Game Changing Life Science Ventures

Endo Investors

About Endo Investors

Endo makes investments in game-changing early-stage companies improving outcomes for large patient populations affected by various chronic diseases. Endo is backed by a group of mission-oriented investors and was created in response to a deficit of early-stage capital focused on companies impacting diabetes and other major global health issues.

Eric Edidin formed Endo Investors in 2013, soon after his then-toddler daughter was diagnosed with type-1 diabetes. Endo portfolio companies have made numerous cutting-edge breakthroughs for the patient populations they serve while simultaneously focusing on strong investor returns.

Mr. Edidin is also president of Three B Holdings, a private family investment company, Executive Chairman of BH3 Management, a real estate investment firm, and co-founded Archer Capital Management, an institutional asset management firm. Previously, he was a portfolio manager and co-head of credit investments at York Capital Management, a member of Morgan Stanley Capital Partners’ global private equity investment team, and Blackstone Group’s restructuring advisory team.

Mr. Edidin was formerly an executive board member of the JDRF of Los Angeles and a member of the investment committee of the Jewish Communal Fund of NY. Mr. Edidin currently serves as an investment committee member of the Jewish Federation of Los Angeles and director of the European Leadership Network (ELNET).

Eric holds a B.B.A. degree with the highest distinction from the University of Michigan, and an M.B.A from Harvard Business School and lives in Southern Florida with his wife and three children.

Portfolio Companies

The game-changing companies we invest in.

Bigfoot Biomedical

Bigfoot Biomedical is dedicated to making lives healthier, safer, and easier by enabling optimized insulin delivery solutions accessible for all.



Biolinq technology utilizes unique data inputs to sense and analyze glucose levels, delivering the first intelligent CGM


Capillary Biomedical

Capillary Biomedical aims to simplify insulin infusions to improve the quality of life for people with diabetes. It first product, the SteadiSet™ infusion set featuring SteadiFlow™ technology, is designed to improve the comfort, reliability and predictability of pump therapy. Capillary Biomedical was acquired by Tandem Diabetes Care (NASDAQ: TNDM) in July 2022.


Cecelia Health

Cecelia Health blends clinical coaching and technology to help individuals and organizations reach their goals.



Diasome is developing hepatocyte directed vesicle (HDV) technology to reduce the incidence of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. HDV technology is being developed as an additive to all forms of insulin to improve its safety and efficacy by restoring the liver’s natural role in blood glucose control.


ILiAD Biotechnologies

ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.


Locemia Solutions

Locemia Solutions has developed a needle-free glucagon rescue treatment for severe hypoglycemia called Baqsimi. The worldwide product rights were sold to Eli Lilly and company (NYSE:LLY) in 2015. Baqsimi was successfully launched commercially in 2019.


Mellitus Health

Mellitus Health’s Insulin Insights™ software makes precision insulin dosing recommendations in seconds, enabling clinicians to optimize insulin regimens—reducing blood glucose, complications, and healthcare costs


Illuminare Biotechnology

Illuminare Biotechnologies is a preclinical stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage.



    Scroll to top